Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature.

Published on Jun 15, 2021in Seminars in Thrombosis and Hemostasis2.892
· DOI :10.1055/S-0041-1729856
Sources
Abstract
The term "lupus anticoagulant (LA)" identifies a form of antiphospholipid antibodies (aPLs) causing prolongation of clotting tests in a phospholipid concentration-dependent manner. LA is one of the laboratory criteria identified in patients with antiphospholipid (antibody) syndrome (APS). The presence of LA in patients with APS represents a significant risk factor for both thrombosis and pregnancy morbidity. There have been several reports of similarities between some of the pathophysiological features of COVID-19 and APS, in particular the most severe form, catastrophic APS. There have also been many reports identifying various aPLs, including LA, in COVID-19 patients. Accordingly, a very pertinent question arises: "Is LA a feature of COVID-19 pathology?" In this review, we critically appraise the literature to help answer this question. We conclude that LA positivity is a feature of COVID-19, at least in some patients, and potentially those who are the sickest or have the most severe infection. However, many publications have failed to appropriately consider the many confounders to LA identification, being assessed using clot-based assays such as the dilute Russell viper venom time, the activated partial thromboplastin time (aPTT), and the silica clotting time. First, most patients hospitalized with COVID-19 are placed on anticoagulant therapy, and those with prior histories of thrombosis would possibly present to hospital already on anticoagulant therapy. All anticoagulants, including vitamin K antagonists, heparin (both unfractionated heparin and low-molecular-weight heparin), and direct oral anticoagulants affect these clot-based assays. Second, C-reactive protein (CRP) is highly elevated in COVID-19 patients, and also associated with severity. CRP can also lead to false-positive LA, particularly with the aPTT assay. Third, persistence of aPL positivity (including LA) is required to identify APS. Fourth, those at greatest risk of thrombosis due to aPL are those with highest titers or multiple positivity. Most publications either did not identify anticoagulation and/or CRP in their COVID-19 cohorts or did not seem to account for these as possible confounders for LA detection. Most publications did not assess for aPL persistence, and where persistence was checked, LA appeared to represent transient aPL. Finally, high titer aPL or multiple aPL positivity were in the minority of COVID-19 presentations. Thus, at least some of the reported LAs associated with COVID-19 are likely to be false positives, and the relationship between the detected aPL/LA and COVID-19-associated coagulopathy remains to be resolved using larger and better studies.
References76
Newest
Coronavirus disease 2019 (COVID-19) is characterized by a procoagulant state that can lead to fatal thromboembolic events. Several studies have documented a high prevalence of lupus anticoagulant that may at least partially explain the procoagulant profile of COVID-19. However, the association between lupus anticoagulant and thrombotic complications in COVID-19 is controversial and no study has specifically evaluated the impact of lupus anticoagulant on mortality. The aim of our study was to inv...
8 CitationsSource
#1Bingwen Eugene FanH-Index: 9
#2Jensen Ng (TTSH: Tan Tock Seng Hospital)H-Index: 2
Last. Yew Woon Chia (TTSH: Tan Tock Seng Hospital)H-Index: 3
view all 15 authors...
Patients with COVID-19 are known to be at risk of developing both venous, arterial and microvascular thrombosis, due to an excessive immuno-thrombogenic response to the SARS-CoV-2 infection. Overlapping syndromes of COVID-19 associated coagulopathy with consumptive coagulopathy and microangiopathy can be seen in critically ill patients as well. Blood was collected from 12 Intensive Care Unit (ICU) patients with severe COVID-19 who were on either mechanical ventilation or on high flow oxygen with...
17 CitationsSource
#1M. Pineton De Chambrun (University of Paris)H-Index: 2
#2Corinne FrereH-Index: 15
Last. Alain Combes (University of Paris)H-Index: 78
view all 8 authors...
Coronavirus disease 2019 (COVID-19) is associated with both severe systemic inflammation and a prothrombotic state, as reflected by significant increases in fibrinogen and D-dimers levels that have been associated with poor prognosis and high rates of severe pulmonary embolism. A recent report suggested a role for antiphospholipid antibodies (aPLA) in the thrombotic manifestations associated with severe COVID-19. As we also recently noticed unexplained lengthening of activated partial thrombopla...
46 CitationsSource
Objectives Antiphospholipid antibodies (APAs) increase the risk of excessive blood clotting, but their role in COVID-19 remains unclear. We aimed to investigate the presence of conventional APAs used in the classification of antiphospholipid antibody syndrome in patients with severe lung infection with SARS-CoV-2 and to compare these results with non-COVID-19 critically ill patients. Methods Thirty-one COVID-19 patients (COVID group) and 28 non-COVID-19 critically ill patients (non-COVID group),...
5 CitationsSource
#1Amer HamadéH-Index: 2
#2Bastien WoehlH-Index: 2
Last. Lucas JambertH-Index: 3
view all 6 authors...
: Antiphospholipid (aPL) antibodies can arise transiently at times of viral diseases. The objective of this work was to evaluate the incidence of aPL antibodies in patients hospitalized in conventional unit for coronavirus disease 2019 (COVID-19) infection and confirmed venous thromboembolic events (VTE) associated with aPL antibodies. 41 patients infected with COVID-19 were tested for aPL antibodies. None had reported history of aPL syndrome. Arterial and venous duplex ultrasound of lower limbs...
6 CitationsSource
#1William J. Jenner (University of Hertfordshire)H-Index: 1
#2Rahim Kanji (NIH: National Institutes of Health)H-Index: 3
Last. Diana A. Gorog (University of Hertfordshire)H-Index: 22
view all 7 authors...
A prothrombotic state is reported with severe COVID-19 infection, which can manifest in venous and arterial thrombotic events. Coagulopathy is reflective of more severe disease and anticoagulant thromboprophylaxis is recommended in hospitalized patients. However, the prevalence of thrombosis on the intensive care unit (ICU) remains unclear, including whether this is sufficiently addressed by conventional anticoagulant thromboprophylaxis. We aimed to identify the rate of thrombotic complications ...
15 CitationsSource
#1Ariella Tvito (Shaare Zedek Medical Center)H-Index: 4
#2Eli Ben-Chetrit (Shaare Zedek Medical Center)H-Index: 10
Last. Yigal Helviz (Shaare Zedek Medical Center)H-Index: 8
view all 5 authors...
8 CitationsSource
#1Alexandre Le Joncour (University of Paris)H-Index: 5
#2Corinne Frere (University of Paris)H-Index: 15
Last. Patrice Cacoub (University of Paris)H-Index: 122
view all 13 authors...
10 CitationsSource
#1Noppacharn Uaprasert (Chula: Chulalongkorn University)H-Index: 6
#2Chatphatai Moonla (Chula: Chulalongkorn University)H-Index: 3
Last. Thita Chiasakul (Chula: Chulalongkorn University)H-Index: 6
view all 5 authors...
Coagulation activation has been reported in several cohorts of patients Coronavirus Disease 2019 (COVID-19). However, the true burden of systemic coagulopathy in COVID-19 remains unknown. In this systematic review and meta-analysis, we performed a literature search using PubMed, EMBASE, and Cochrane Database to identify studies that reported the prevalence of systemic coagulopathy using established criteria in patients with COVID-19. The primary outcome was the prevalence of systemic coagulopath...
6 CitationsSource
#1Wolfgang Bauer (Humboldt University of Berlin)H-Index: 3
#2Noa Galtung (Humboldt University of Berlin)H-Index: 2
Last. Kai Kappert (Charité)H-Index: 24
view all 8 authors...
COVID-19 (coronavirus disease 2019) patients often show excessive activation of coagulation, associated with increased risk of thrombosis. However, the diagnostic value of coagulation at initial clinical evaluation is not clear. We present an in-depth analysis of coagulation in patients presenting to the emergency department (ED) with suspected COVID-19. N = 58 patients with clinically suspected COVID-19 in the ED were enrolled. N = 17 subsequently tested positive using SARS-CoV-2 (severe acute ...
3 CitationsSource
Cited By2
Newest
COVID-19 (coronavirus disease 2019) represents a pandemic, and several vaccines have been produced to prevent infection and/or severe sequelae associated with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection. There have been several reports of infrequent post vaccine associated thrombotic events, in particular for adenovirus-based vaccines. These have variously been termed VIPIT (vaccine-induced prothrombotic immune thrombocytopenia), VITT (vaccine-induced [immune] thrombot...
1 CitationsSource
Antiphospholipid antibodies (aPL) comprise a panel of autoantibodies that reflect a potential prothrombotic risk in several autoimmune conditions, most notably antiphospholipid (antibody) syndrome (APS) null aPL can be divided into those that form part of the laboratory criteria for APS, namely, lupus anticoagulant (LA), as well as anticardiolipin antibodies (aCL) and anti-beta2-glycoprotein I antibodies (abeta2GPI) of the immunoglobulin G and M classes, and those that form a group considered as...
1 CitationsSource